Progyny, Inc. $PGNY Position Boosted by WINTON GROUP Ltd

WINTON GROUP Ltd increased its position in Progyny, Inc. (NASDAQ:PGNY) by 266.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 251,834 shares of the company’s stock after purchasing an additional 183,163 shares during the period. WINTON GROUP Ltd owned 0.33% of Progyny worth $7,260,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares in the last quarter. Teza Capital Management LLC grew its position in shares of Progyny by 5.4% in the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after acquiring an additional 516 shares in the last quarter. Aristides Capital LLC increased its holdings in shares of Progyny by 4.6% in the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after acquiring an additional 528 shares during the last quarter. Oxford Asset Management LLP increased its holdings in shares of Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after acquiring an additional 531 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Progyny by 3.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 19,202 shares of the company’s stock valued at $493,000 after acquiring an additional 637 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Price Performance

Shares of PGNY opened at $27.12 on Thursday. The company has a market cap of $2.08 billion, a P/E ratio of 29.48, a PEG ratio of 1.87 and a beta of 0.99. The stock has a fifty day moving average price of $28.83 and a 200 day moving average price of $23.95. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the business posted $0.19 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 1.25 earnings per share for the current year.

Progyny declared that its board has initiated a share repurchase plan on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to purchase up to 10.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several research analyst reports. BTIG Research raised their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Barclays reduced their price target on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Weiss Ratings lowered shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, Canaccord Genuity Group set a $35.00 price objective on shares of Progyny in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.36.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.